安络化纤丸联合恩替卡韦治疗代偿期乙肝肝硬化临床疗效

Effect of Anluo Huaxian Pills(安络化纤丸)Combined with Entecavir inTreatment of Compensatory Hepatitis B Cirrhosis

目的观察调肝化纤丸联合恩替卡韦治疗代偿期乙肝肝硬化疗效。方法选择114例乙肝肝硬化代偿期患者分为观察组和对照组各57例。对照组口服恩替卡韦片,观察组联合安络化纤丸,均治疗6个月。结果治疗后,观察组总胆红素(TBIL)、谷氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、HBV-DNA载量、肝纤维化各项指标及中医证候积分均明显低于对照组(P<0.05);观察组总有效率84.4%(38/45),高于对照组的64.4%(29/45)(P<0.01)。结论乙肝肝硬化代偿期患者在恩替卡韦抗病毒治疗基础上联合安络化纤丸能够增强抑制病毒复制效果,改善肝功能及纤维化状态。

Objective To investigate the effect of Anluo Huaxian Pill(安络化纤丸) scombined with entecavir in the treatment of compensatory hepatitis B cirrhosis. Methods A total of 114 patients with compensatory hepatitis B cirrhosis were selected and divided into observation group and control group, 57 cases in each group. The control group were treated with entecavir. On the basis, the observation group were treated with Anluo Huaxian Pills. The course of treatment lasted for 6 mouths. Results After treatment, the levels of TBIL, ALT and AST, HBV-DNA, liver fibrosis index and TCM syndrome integralof the patients in observation group were lower than those in control group(P<0.05). The total effective rate of the observation group was 84.4%(38/40), which was higher than 64.4%(29/45) of the control group(P<0.01). Conclusion Anluo Huaxian Pills combined with entecavir can enhance the effect of inhibiting virus replication and improve liver function and fibrosis.